Research Article
Melatonin in Tuberous Sclerosis Complex Analysis Using Modern Mathematical Modeling Methods
Table 1
Patients’ presentation and estimated parameters of the model of melatonin secretion.
| | Patient 1
5 yrs 7 mo (f) | Patient 2
5 yrs (f) | Patient 3
6 yrs (f) | Patient 4
2 yrs 10 mo (f) |
| | Family history | Nonrelevant | Nonrelevant | Nonrelevant | Nonrelevant | | Gestation, delivery period | Nonrelevant | Nonrelevant | Nonrelevant | Nonrelevant | | Epilepsy | Since 6 mo | Since 3 mo | Since 5 mo | Since 6 mo | | Cognitive level | Severe
impairment | Severe
impairment | Severe
impairment | Severe impairment | | EEG | Paroxysmal
changes R > L | Paroxysmal
changes R > L | Paroxysmal
changes R > L | Paroxysmal changes
with right fronto-centro-temporal
predominance | Average number of epileptic seizures
a day | 4 | 1 | 2 | 1 | Number of epileptic seizures a day
before melatonin secretion assessment | — | 1 | 1 | — | Number of epileptic seizures a day
during melatonin secretion assessment | — | — | — | — | Antiepileptic drugs
(during melatonin measurement) | Valproic acid,
vigabatrin | Valproic acid,
vigabatrin | Valproic acid,
vigabatrin, levetiracetam | Valproic acid, vigabatrin | | Minimum melatonin concentration (pg/mL) | 15.13 | 7.38 | 4.66 | The melatonin flux did
not take place | | Melatonin release amplitude (pg/mL) | 250.04 | 394.65 | 93.45 | | Phase shift of melatonin release (h) | 4.89 | 2.66 | 2.71 | | Estimated sleep duration (h) | 5.8 | 4.5 | 8.85 | | Maximum melatonin concentration (pg/mL) | 265.17 | 402.03 | 98.11 | | (h) | 1.99 | 0.41 | 22.29 | | (h) | 7.8 | 4.91 | 7.14 | | (h) | 1.20 | 23.79 | 21.08 | | (h) | 8.59 | 5.53 | 8.56 |
|
|
Time in a decimal system.
|
